Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

person Alexios Matikas Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden info_outline Alexios Matikas, Hemming Johansson, Per Grybäck, Judith Bjöhle, Tobias Lekberg, Hanna Fredholm, Balazs Acs, Ellinor Elinder, Erika Isaksson-Friman, Susanne Agartz, Mats Hellstrom, Ioannis Zerdes, Johan Hartman, Jonas C. S. Bergh, Thomas Hatschek, Theodoros Foukakis

Authors person Alexios Matikas Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden info_outline Alexios Matikas, Hemming Johansson, Per Grybäck, Judith Bjöhle, Tobias Lekberg, Hanna Fredholm, Balazs Acs, Ellinor Elinder, Erika Isaksson-Friman, Susanne Agartz, Mats Hellstrom, Ioannis Zerdes, Johan Hartman, Jonas C. S. Bergh, Thomas Hatschek, Theodoros Foukakis Organizations Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, Karolinska Institutet and Södersjukhuset, Stockholm, Sweden, Department of Oncology, South Hospital, Stockholm, Stockholm, Sweden, Department of Oncology, St Göran Hospital, Stockholm, Sweden, Central Trial Office, Clinical Trial Unit, Karolinska University Hospital, Stockholm, Sweden, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Stockholm, Sweden Abstract Disclosures Research Funding Other Government Agency Background: Abundance of tumor infiltrating lymphocytes (TIL) is prognostic in early HER2-positive breast cancer (BC). Response to neoadjuvant therapy (NAT) according to positron emission tomography combined with computed tomography (PET-CT) has been shown to predict pathologic complete response (pCR). There is paucity of data regarding long-term prognostication using PET-CT and the potential value of the combined assessment of both these biomarkers. Methods: PREDIX HER2 (NCT02568839) is a prospective randomized phase 2 trial that compared standard NAT (docetaxel, trastuzumab, pertuzumab) with trastuzumab emtansine, in patients with HER2-positive BC. Overall, 202 patients were included (197 evaluable) and the primary efficacy analysis showed no difference in pCR or event-free survival (EFS) between the two groups (Hatschek, JAMA Oncology 2021). Assessment with fluorine 18–labeled fluorodeoxyglucose PET-CT was performed at baseline and after 2 and 6 treatment cycles, and SUVmax was evaluated as a continuous variable. TILs were assessed at baseline biopsies according to guidelines from the International TIL Working Group (J.H.). The aim of this secondary analysis was to investigate the combined assessment of TIL and PET-CT as an early predictor of response to NAT. Results: Overall, 112 patients underwent baseline PET-CT and 109 after C2, whereas 173 had baseline TIL. In multivariable analysis, baseline SUVmax did not predict pCR (OR adj = 1.04, 95% CI 0.97-1.12, p = 0.259) or EFS (HR adj = 1.07, 95% CI 0.98-1.17, p = 0.117). In contrast, higher SUVmax at C2 predicted lower pCR (OR adj = 0.65, 95% CI 0.48-0.87, p = 0.005) and worse EFS (HR adj = 1.18, 95% CI 1.04-1.34, p = 0.01). Baseline TIL > 10% (median cut-off) provided additional prognostic information to clinical parameters (stage and hormone receptor expression) and C2 SUVmax (LR-Δχ 2 = 7.19, p = 0.007; OR adj = 3.52, 95% CI 1.37 – 9.06, p = 0.009). 75% of patients with high TIL and C2 SUVmax < 2.49 achieved pCR, compared with 13.8% of those with low TIL and high C2 SUVmax and 39.1%-41.3% for the intermediate groups (p = 0.001). Conclusions: SUVmax after two cycles of NAT for HER2-positive BC is an independent predictor of both short- and long-term outcomes. A combined assessment with TIL may facilitate early selection of good responders for de-escalation and poor responders for alternative treatment strategies. Clinical trial information: NCT02568839.